CORRECTION article

Front. Med., 19 May 2025

Sec. Ophthalmology

Volume 12 - 2025 | https://doi.org/10.3389/fmed.2025.1620932

Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema

This article is a correction to:

  1. Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema

    1. Read original article
Gaixia ZhaiGaixia ZhaiChao SunChao SunXia ZhangXia ZhangYuanzhen Su Yuanzhen Su*
  • Zibo Central Hospital, Zibo, China

A corrigendum on
Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema

by Zhai, G., Sun, C., Zhang, X., and Su, Y. (2025). Front. Med. 12:1528104. doi: 10.3389/fmed.2025.1528104

In the published article, the reference for (5) was incorrectly written as “Georgalas, L, Tservakis, I, Kiskira, EE, Petrou, P, Papaconstantinou, D, and Kanakis, M. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:330–7. doi: 10.31348/2025/4.” It should be “Berhuni M, Yılmaz İE, Gizem GS, Özcan ZÖ, Doğan L. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:1–6. doi: 10.31348/2025/4.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

5. Berhuni M, Yılmaz İE, Gizem GS, Özcan ZÖ, Doğan L. Efficacy and safety of intravitreal dexamethasone implant in treatment-resistant diabetic macular edema: six-month results. Cesk Slov Oftalmol. (2025) 81:1–6. doi: 10.31348/2025/4

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: aflibercept biosimilar, diabetic macular edema, foveal avascular zone, vascular density, multifocal electroretinography

Citation: Zhai G, Sun C, Zhang X and Su Y (2025) Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema. Front. Med. 12:1620932. doi: 10.3389/fmed.2025.1620932

Received: 30 April 2025; Accepted: 05 May 2025;
Published: 19 May 2025.

Edited and reviewed by: Yi Du, The First Affiliated Hospital of Guangxi Medical University, China

Copyright © 2025 Zhai, Sun, Zhang and Su. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Yuanzhen Su, eXVhbnpoZW5oYW9yZW5AMTI2LmNvbQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.